Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...
TipRanks on MSN
Biogen, Eisai say Leqembi BLA accepted in China
Eisai (ESALY) and Biogen (BIIB) announced that the Biologics License Application for the subcutaneous formulation of LEQEMBI, an anti-amyloid beta ...
In the third quarter, lower sales of Biogen’s multiple sclerosis (“MS”) drugs are likely to have been offset by sequential revenue growth from new products. Sales of Biogen’s MS drugs like Tecfidera ...
Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results